

1 August 2017

PureTech Health plc

Notice of Half-Yearly Results

PureTech Health plc ("PureTech", LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, expects to announce its half-yearly results for the six months ended 30 June 2017 at 7.00am BST on Wednesday 30 August 2017.

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the immune, nervous, and gastro-intestinal systems by intervening early and addressing the underlying pathophysiology of disease. The Company is advancing a rich pipeline that includes two pivotal or registration studies expected to read out in 2017, multiple human proof-of-concept studies and a number of early clinical and pre-clinical programmes. PureTech Health's growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts, who along with PureTech's experienced team and a stellar Board identify, analyse and advance very selectively the opportunities the Company believes hold the most promise for patients. This experienced and engaged team places PureTech Health at the forefront of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter [@puretechh](https://twitter.com/puretechh).

Contact:

PureTech Health

Allison Mead
+1 617 651 3156
amead@puretechhealth.com

FTI Consulting

Ben Atwell, Rob Winder
+44 (0) 20 3727 1000